Chemokine Receptor CXCR4-targeting PET Imaging for Thymoma
试验速览
- 阶段
- 早期 1 期
- 状态
- 招募中
- 入组人数
- 100
- 试验地点
- 1
- 主要终点
- SUVmax and SUVmean
研究概览
简要总结
Chemokine receptor CXCR4 was expressed in T cells and CXCR4-targeting molecular imaging- 68Ga-Pentixafor PET/CT could be a promising technique to evaluate the extent of thymoma with higher accuracy. This prospective study is going to investigate whether metabolic characterization by 68Ga-Pentixafor PET/CT may be superior for diagnosis, distinguish evaluation for thymoma.
详细描述
Thymoma is 1 rare type of tumor developed on the thymic epithelium; patients with thymoma also might have myasthenia gravis (MG). Because of the scarcity and complexity of MG-associated thymoma, its pathogenesis and etiology still remain unclear nowadays. The expression of C-X-C chemokine receptor type 4 (CXCR4) is absent or low in most healthy tissues but highly expressed in various types of tumors. CXCR4 might contribute to the clinical cancer progression, and CXCR4 could be a valuable prognostic biomarker in the therapy of MG-associated thymoma.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •suspected or confirmed untreated thymoma patients
- •signed written consent.
排除标准
- •pregnancy
- •breastfeeding
- •known allergy against Pentixafor
- •any medical condition that in the opinion of the investigator,may
- •significantly interfere with study compliance.
研究组 & 干预措施
68Ga-Pentixafor, PET/CT
Inject 68Ga-Pentixafor and then perform PET/CT scan.
干预措施: 68Ga-Pentixafor (Drug)
结局指标
主要结局
SUVmax and SUVmean
时间窗: through study completion, an average of 1.5 years
SUVsof focal lesions are measured on 68Ga-Pentixafor PET/CT. The SUVs of the blood pool and muscle are defined as the background activity on the condition that there is no focally hypermetabolic disease.
次要结局
- Diagnostic value(through study completion, an average of 1.5 years)
- Diagnostic value in special type of thymoma(through study completion, an average of 1.5 years)
- CXCR4 expression and SUV(through study completion, an average of 1.5 years)
- Diagnostic value in thymoma and other masses(through study completion, an average of 1.5 years)